β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22378044.
- Also identified by DOI 10.1172/JCI61350 and PMC identifier 3314473.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Integrin signaling critically contributes to the progression, growth, and therapy resistance of malignant tumors. Here, we show that targeting of β₁ integrins with inhibitory antibodies enhances the sensitivity to ionizing radiation and delays the growth of human head and neck squamous cell carcinoma cell lines in 3D cell culture and in xenografted mice. Mechanistically, dephosphorylation of focal adhesion kinase (FAK) upon inhibition of β₁ integrin resulted in dissociation of a FAK/cortactin protein complex. This, in turn, downregulated JNK signaling and induced cell rounding, leading to radiosensitization. Thus, these findings suggest that robust and selective pharmacological targeting of β₁ integrins may provide therapeutic benefit to overcome tumor cell resistance to radiotherapy.
Medical subject headings
- Carcinoma, Squamous Cell
- Cortactin
- Focal Adhesion Kinase 1
- Head and Neck Neoplasms
- Integrin beta1
- Neoplasm Proteins
- Radiation Tolerance